Translate:

Baker McKenzie advised the German biotech company MODAG on the in-licensing of an innovative substance portfolio (SERY 433) from Max Planck Innovation GmbH to combat neurodegenerative diseases and on the closing of a € 12 million Series A financing round, led by the Massa Investment AG, Switzerland.

Baker McKenzie advised MODAG on all legal and tax aspects in connection with the in-licensing of the substance portfolio and the completed Series A Financing.

"We were able to efficiently support our client with our outstanding legal expertise coupled with special life science know-how in this exciting Series A Financing as well as with regard to the in-licensing," comments Julia Braun, Corporate/M&A Counsel at Baker McKenzie in Munich.

The MODAG GmbH, located at the high-technology park in Wendelsheim, Germany, deals with the research and development of therapeutics and diagnostics for neurodegenerative diseases. MODAG GmbH’s innovative approach offers a unique combination of early diagnosis and targeted disease modifying therapies.

Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, serves as a link between industry and basic research. With its interdisciplinary team, it advises and supports scientists in evaluating their inventions, filing patents, and founding companies.

Baker McKenzie's Corporate / M&A team regularly advises big pharma, financial investors and early stage biotech companies on domestic and international healthcare transactions. Most recently, Baker McKenzie advised Hitachi Chemical on the acquisition of apceth Biopharma, Forbion as lead investor on a € 17 million Series C Equity Financing of Omeicos Therapeutics as well as on a USD 54 million Series A Equity Financing of Gotham Therapeutics Corporation, Mundipharma on the sale of its Limburg production, CureVac AG on a collaboration with Eli Lilly and Hillhouse Capital as co-investor in the € 50 million Series C cross-over financing of Hookipa Biotech.

Legal Advisor to MODAG GmbH: Baker McKenzie

Lead: Julia Braun (Corporate/M&A, counsel, Munich)

Team:                                         

Corporate/M&A: Berthold A. Hummel (partner, Munich), Dr. Julia Rossié (associate, Munich), Dr. Björn Bastian Boerger (associate, Munich)

Employment: Dr. Matthias Köhler (senior associate, Berlin)

Tax: Dr. Christian Port (partner, Frankfurt), Eva Jürgens (associate, Frankfurt)
Explore Our Newsroom
See All News